BACKGROUND & AIMS: Recent studies have suggested that the kallikrein-kinin system regulates tissue fibrogenesis. We hypothesize that bradykinin (BK), the main effector peptide of this system, regulates hepatic fibrogenesis. METHODS: Kallikrein-kinin system components were studied by quantitative reverse-transcription polymerase chain reaction analysis, immunohistochemistry, and Western blotting. The effect of bradykinin on liver injury was studied by infusing saline or bradykinin (1 and 100 ng/kg/min) through a subcutaneous pump into carbon tetrachloride-treated rats and mice treated with Fas-stimulating antibody. Bradykinin effects were studied in cultured hepatic stellate cells (HSCs) and hepatocytes. RESULTS: Bradykinin receptors and kallikrein-1 were detected in both normal and fibrotic human livers and HSCs. BK receptors were up-regulated in fibrotic livers and activated HSCs. Bradykinin infusion reduced liver damage, as indicated by decreased aminotransferase serum levels and reduced histologic necroinflammatory score without inducing changes in arterial pressure. Moreover, bradykinin attenuated hepatic fibrosis, as indicated by reduced collagen accumulation, smooth muscle alpha-actin content, as well as decreased pro-collagen-alpha1(I) and transforming growth factor-beta1 gene expression. Bradykinin infusion reduced hepatocellular apoptosis induced by anti-Fas-receptor antibody. HSCs responded to bradykinin with intracellular calcium mobilization. Bradykinin reduced procollagen-alpha1(I) and transforming growth factor-beta1 gene expression and induced matrix metalloproteinase-2 activation. Finally, BK induced prosurvival and proliferative intracellular signaling in primary hepatocytes. CONCLUSIONS: Bradykinin attenuates liver damage and fibrosis development in a rat model of chronic liver injury. Therefore, activation of the kallikrein-kinin system may be a new therapeutic approach to the management of chronic liver disease.
BACKGROUND & AIMS: Recent studies have suggested that the kallikrein-kinin system regulates tissue fibrogenesis. We hypothesize that bradykinin (BK), the main effector peptide of this system, regulates hepatic fibrogenesis. METHODS: Kallikrein-kinin system components were studied by quantitative reverse-transcription polymerase chain reaction analysis, immunohistochemistry, and Western blotting. The effect of bradykinin on liver injury was studied by infusing saline or bradykinin (1 and 100 ng/kg/min) through a subcutaneous pump into carbon tetrachloride-treated rats and mice treated with Fas-stimulating antibody. Bradykinin effects were studied in cultured hepatic stellate cells (HSCs) and hepatocytes. RESULTS: Bradykinin receptors and kallikrein-1 were detected in both normal and fibrotic human livers and HSCs. BK receptors were up-regulated in fibrotic livers and activated HSCs. Bradykinin infusion reduced liver damage, as indicated by decreased aminotransferase serum levels and reduced histologic necroinflammatory score without inducing changes in arterial pressure. Moreover, bradykinin attenuated hepatic fibrosis, as indicated by reduced collagen accumulation, smooth muscle alpha-actin content, as well as decreased pro-collagen-alpha1(I) and transforming growth factor-beta1 gene expression. Bradykinin infusion reduced hepatocellular apoptosis induced by anti-Fas-receptor antibody. HSCs responded to bradykinin with intracellular calcium mobilization. Bradykinin reduced procollagen-alpha1(I) and transforming growth factor-beta1 gene expression and induced matrix metalloproteinase-2 activation. Finally, BK induced prosurvival and proliferative intracellular signaling in primary hepatocytes. CONCLUSIONS: Bradykinin attenuates liver damage and fibrosis development in a rat model of chronic liver injury. Therefore, activation of the kallikrein-kinin system may be a new therapeutic approach to the management of chronic liver disease.
Authors: María José Acuña; Daniela Salas; Adriana Córdova-Casanova; Meilyn Cruz-Soca; Carlos Céspedes; Carlos P Vio; Enrique Brandan Journal: J Cell Commun Signal Date: 2017-12-17 Impact factor: 5.782
Authors: Christoph H Osterreicher; Kojiro Taura; Samuele De Minicis; Ekihiro Seki; Melitta Penz-Osterreicher; Yuzo Kodama; Johannes Kluwe; Manfred Schuster; Gavin Y Oudit; Josef M Penninger; David A Brenner Journal: Hepatology Date: 2009-09 Impact factor: 17.425
Authors: Carlos C Barros; Anderson Haro; Fernanda J V P Russo; Ines Schadock; Sandro S Almeida; Rosane A Ribeiro; Emerielle C Vanzela; Valeria P Lanzoni; Flavio C Barros; Milton R Moraes; Marcelo A Mori; Reury F P Bacurau; Martin Wurtele; Antônio C Boschero; Everardo M Carneiro; Michael Bader; Joao B Pesquero; Ronaldo C Araujo Journal: PLoS One Date: 2012-07-19 Impact factor: 3.240
Authors: Chih-Chang Wei; Yuanwen Chen; Lindsay C Powell; Junying Zheng; Ke Shi; Wayne E Bradley; Pamela C Powell; Sarfaraz Ahmad; Carlos M Ferrario; Louis J Dell'Italia Journal: PLoS One Date: 2012-06-29 Impact factor: 3.240
Authors: Mar Coll; Adil El Taghdouini; Luis Perea; Inge Mannaerts; Maria Vila-Casadesús; Delia Blaya; Daniel Rodrigo-Torres; Silvia Affò; Oriol Morales-Ibanez; Isabel Graupera; Juan José Lozano; Mustapha Najimi; Etienne Sokal; Joeri Lambrecht; Pere Ginès; Leo A van Grunsven; Pau Sancho-Bru Journal: Sci Rep Date: 2015-06-22 Impact factor: 4.379
Authors: Lamiaa A Ahmed; Fatma Y Abdou; Abir A El Fiky; Esmat A Shaaban; Afaf A Ain-Shoka Journal: Cardiovasc Toxicol Date: 2020-08-29 Impact factor: 3.231
Authors: Piero Bagnaresi; Nilana Mt Barros; Diego M Assis; Pollyana Ms Melo; Raphael G Fonseca; Maria A Juliano; João B Pesquero; Luiz Juliano; Philip J Rosenthal; Adriana K Carmona; Marcos L Gazarini Journal: Malar J Date: 2012-05-07 Impact factor: 2.979